文献速递炎症性肠病

克罗恩病随机临床试验中的安慰剂率:个体患者数据荟萃分析

Placebo Rates in Crohn's Disease Randomized Clinical Trials: An Individual Patient Data Meta-Analysis.
PubMed 文献 · Gastroenterology · 2024-10-15

该研究基于2010-2021年8项诱导试验(n=1147)和4项维持试验(n=524)的个体患者数据,采用1阶段和2阶段荟萃分析方法评估中重度克罗恩病试验的安慰剂率。诱导期安慰剂临床应答率和缓解率分别为27%(95%CI 23%-32%)和10%(95%CI 8%-14%),维持期分别为32%(95%CI 23%-42%)和22%(95%CI 14%-33%)。基线C反应蛋白较高预测较低安慰剂率,而基线白蛋白和体重指数较高增加安慰剂结局的比值。

要点

  • 诱导期安慰剂临床应答率为27%(95%CI 23%-32%),缓解率为10%(95%CI 8%-14%)
  • 维持期安慰剂临床应答率为32%(95%CI 23%-42%),缓解率为22%(95%CI 14%-33%)
  • 基线C反应蛋白较高预测较低安慰剂率,基线白蛋白和体重指数较高增加安慰剂结局的比值

核心结论

  • 患者水平和试验水平特征影响克罗恩病试验中的安慰剂率。
  • 作者认为,仔细实施入选标准、结局定义和患者分层可能降低安慰剂率。

研究设计与样本

  • 研究为对2010-2021年中重度克罗恩病先进疗法安慰剂对照2/3期试验的荟萃分析。
  • 通过Vivli Inc和耶鲁大学开放数据访问项目获取去标识化个体患者数据。
  • 纳入8项诱导试验(n=1147)和4项维持试验(n=524)的个体患者数据。
  • 主要结局为临床应答和缓解,采用1阶段和2阶段荟萃分析方法估计汇总安慰剂率及95%置信区间。
  • 采用回归分析识别与安慰剂率相关的患者水平因素。

主要发现

  • 诱导期总体安慰剂临床应答率为27%(95%CI 23%-32%),缓解率为10%(95%CI 8%-14%)。
  • 维持期总体安慰剂临床应答率为32%(95%CI 23%-42%),缓解率为22%(95%CI 14%-33%)。
  • 诱导期生物制剂初治患者安慰剂应答率为29%(95%CI 24%-35%),缓解率为11%(95%CI 8%-15%);生物制剂经治患者应答率为26%(95%CI 20%-33%),缓解率为10%(95%CI 8%-14%)。
  • 维持期生物制剂初治患者安慰剂应答率为41%(95%CI 34%-48%),缓解率为32%(95%CI 24%-40%);生物制剂经治患者应答率为29%(95%CI 24%-34%),缓解率为16%(95%CI 13%-21%)。
  • 基线C反应蛋白较高预测较低安慰剂率,基线白蛋白较高和体重指数较高增加安慰剂结局的比值;基线克罗恩病活动指数和2项患者报告结局评分较高预测诱导期较高应答率、维持期较低应答率以及诱导期和维持期较低缓解率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Understanding placebo rates is critical for efficient clinical trial design. We assessed placebo rates and associated factors using individual patient data from Crohn's disease trials. METHODS: We conducted a meta-analysis of phase 2/3 placebo-controlled trials evaluating advanced therapies in moderate to severe Crohn's disease (2010-2021). Deidentified individual patient data were obtained through Vivli Inc and the Yale University Open Data Access Project. Primary outcomes were clinical response and remission. Pooled placebo rates and 95% confidence intervals (CIs) were estimated using 1- and 2-stage meta-analytic approaches. Regression analyses identified patient-level factors associated with placebo rates. RESULTS: Analysis of individual patient data from 8 induction (n = 1147) and 4 maintenance (n = 524) trials showed overall placebo clinical response and remission rates for induction were 27% (95% CI, 23%-32%) and 10% (95% CI, 8%-14%), respectively, and 32% (95% CI, 23%-42%) and 22% (95% CI, 14%-33%) for maintenance, respectively. Among biologic (bio)-naïve patients, placebo response and remission rates during induction were 29% (95% CI, 24%-35%) and 11% (95% CI, 8%-15%) respectively, and 26% (95% CI, 20%-33%) and 10% (95% CI, 8%-14%) for biologic (bio)-exposed patients, respectively. During maintenance, biologic-naïve response and remission rates were 41% (95% CI, 34%-48%) and 32% (95% CI, 24%-40%), respectively, and 29% (95% CI, 24%-34%) and 16% (95% CI, 13%-21%) for bio-exposed, respectively. Higher baseline C-reactive protein concentration predicted lower placebo rates, whereas higher baseline albumin levels and body mass index increased the odds of placebo outcomes. Increased baseline Crohn's Disease Activity Index and 2-item patient-reported outcome scores predicted higher response rates in induction, lower response rates in maintenance, and lower remission rates in induction and maintenance. CONCLUSIONS: Patient- and trial-level characteristics influence placebo rates in Crohn's disease trials. Careful implementation of eligibility criteria, outcome definitions, and patient stratification may reduce placebo rates.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Solitano V, Hogan M, Singh S, et al. Placebo Rates in Crohn's Disease Randomized Clinical Trials: An Individual Patient Data Meta-Analysis. Gastroenterology. 2024. PMID: 39414161. doi:10.1053/j.gastro.2024.10.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。